FDA approves Dextenza for the treatment of itching eye associated with allergic conjunctivitis

Compilenewborn

Recently, Ocular Therapeutix announced that the U.

Dextenza is a preservative-free lacrimal insert that releases the corticosteroid dexamethasone in a dose of 0.

It is worth mentioning that Dextenza is the first small tube insert approved by the FDA.

Dextenza was originally approved in December 2018 for the treatment of eye pain after eye surgery

Allergic conjunctivitis is a common eye disease, and topical steroids are an important part of the clinical treatment of this disease

The efficacy and safety of Dextenza in the treatment of allergic conjunctivitis-related ocular itching have been confirmed in 3 randomized, multi-center, double-blind, parallel group, and vehicle-controlled studies

In all three trials, Dextenza exhibited a low mean ocular itching score at all time points during the 30-day study period

It has been observed that Dextenza has good safety and is generally well tolerated in clinical populations with allergic conjunctivitis and ocular inflammation and pain

In the pooled analysis of allergic conjunctivitis studies, the most common ocular adverse events were: increased intraocular pressure (3%), increased tearing (1%), ocular secretions (1%), and decreased vision (1%)

Reference source:

Ocular Therapeutix Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA (dexamethasone ophthalmic insert) 0.